Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.13.1 (
exoribonuclease
)
732
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The length of
casein
mRNA from the lactating mouse mammary gland, as assessed on Northern blots, is shorter after weaning, but is elongated following the removal of milk. In order to investigate this phenomenon, the molecular structures of beta- and gamma-
casein
mRNAs were analysed. The coding and non-coding regions of the two forms were the same length, but the long form of
casein
mRNA had a longer poly(A) tail than the short form (P<0.05). In order to examine the stability of
casein
mRNA under identical conditions,
casein
mRNAs with the long and short poly(A) tails were incubated in the rabbit reticulocyte lysate (RRL) cell-free translation system.
Casein
mRNA with the long poly(A) tail had a longer half-life than that with the short tail (P<0.05). The beta- and gamma-
casein
mRNAs were first degraded into 0.92 and 0.81 kb fragments respectively. With undegraded mRNA, the poly(A) tail shortening by
exoribonuclease
was not observed until the end of the incubation. Northern blot analysis showed that
casein
mRNA with the long poly(A) tail was protected efficiently from endoribonucleases. We conclude that the length of the poly(A) tail of
casein
mRNA in the lactating mammary gland changes depending upon the accumulation and removal of the gland's milk, and we show that the longer poly(A) tail potentially protects the mRNA from degradation by endoribonucleases.
...
PMID:The poly(A) tail length of casein mRNA in the lactating mammary gland changes depending upon the accumulation and removal of milk. 1074 89